CHEST Physician
-
Opening the flood gates: Pleural complications of immune checkpoint inhibitors
The pulmonary and medical oncology community must start to consider pleural complications as a potential risk of immune checkpoint inhibitor therapy.
-
Pooled data suggest sotatercept as novel disease-modifying therapy for PAH
Aaron B. Waxman, MD, PhD, FCCP, said he believes the drug will become a first-line therapy option, but questions remain regarding when to initiate treatment.
-
Top-line results from FIBRONEER-ILD point to possible third agent for interstitial lung disease
If the data prove accurate, Barry Shea, MD, said nerandomilast could become the first new treatment for lung fibrosis in more than a decade.
-
Advanced practice respiratory therapist: The new advanced practice provider
The rise of the advanced practice respiratory therapist marks a pivotal advancement in respiratory care, addressing the growing need for specialized providers in health care.
-
Tezepelumab trial demonstrates solid results for treatment of CRSwNP
Joseph K. Han, MD, said the data showed the highest change in sinonasal outcome test scores from baseline compared with any other biologic studies for chronic rhinosinusitis with nasal polyps.
-
Turning the tide in right ventricular failure: The role of mechanical support
As mechanical circulatory support technologies advance, understanding the unique features of right-sided devices is essential for optimal patient selection.
-
Capillary refill time: Advancing perfusion-targeted resuscitation in septic shock
Capillary refill time is a quick, noninvasive tool to assess perfusion and microvascular health in shock. It offers faster feedback than lactate levels and may improve resuscitation outcomes.
-
Delving deeper into the molecular genetics of idiopathic pulmonary fibrosis
William Whalen II, MD, MS, reflects on his experience as a recipient of the 2023 CHEST Research Grant in Pulmonary Fibrosis and how it has affected his professional trajectory.
-
Top reads from the CHEST journal portfolio – May 2025
Editorial Board members share their insights on journal articles about CT scan analysis in RA-ILD, asthma and COPD exacerbations in adults in the ICU, and racialized economic disparities in NSCLC care and outcomes.
-
COPD: Could there be a GLP-1 for that?
While real-world data are promising, experts Dinah Foer, MD, and William B. Feldman, MD, say more randomized controlled trials are needed to confirm whether antihyperglycemic medications can improve respiratory outcomes in patients with comorbid type 2 diabetes and COPD.
